Proneurogenic compounds have recently shown promise in some mouse models of Alzheimer’s pathology. Antagonists at Group II metabotropic glutamate receptors (Group II mGluR: mGlu2, mGlu3) are ...

NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development BEDMINSTER, N.J., Oct. 9 -- NPS Pharmaceuticals announced today that by ...

Starting in 2001, FRAXA organized a concerted effort in university labs around the world to confirm Mark Bear's mGluR Theory of Fragile X and to demonstrate to pharmaceutical companies that mGluR5 ...